Canna~Fangled Abstracts

CBD: A New Hope?

By April 29, 2019May 18th, 2019No Comments
2019 Apr 29;10(5):694-695. doi: 10.1021/acsmedchemlett.9b00127. eCollection 2019 May 9.

Abstract

The nonpsychoactive phytocannabinoid, CBD, was recently approved by the Food and Drug Administration for the treatment of children with drug-resistant epilepsy. This milestone opens new avenues for cannabinoid research. In this Viewpoint, we provide an overview of recent progress in the field highlighting molecular insights into CBD’s mechanism of action, as well as its therapeutic potential.

PMID: 31097982
PMCID: PMC6511966
[Available on 2020-05-09]
DOI: 10.1021/acsmedchemlett.9b00127

Conflict of interest statement

The authors declare no competing financial interest.

Publication type

Publication type

Leave a Reply